Esperion Therapeutics ESPR Operating Lease Liability Payments - 2026 (Lessee)
Operating Lease Liability Payments - 2026 (Lessee) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's operating lease liability payments - 2026 (lessee).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's operating lease liability payments - 2026 (lessee)?
- Esperion Therapeutics (ESPR) reported operating lease liability payments - 2026 (lessee) of $258K in Q4 2025.
- How has Esperion Therapeutics's operating lease liability payments - 2026 (lessee) changed year-over-year?
- Esperion Therapeutics's operating lease liability payments - 2026 (lessee) increased by 7.1% year-over-year, from $241K to $258K.
- What is the long-term trend for Esperion Therapeutics's operating lease liability payments - 2026 (lessee)?
- Over 5 years (2020 to 2025), Esperion Therapeutics's operating lease liability payments - 2026 (lessee) has grown at a -20.8% compound annual growth rate (CAGR), from $830K to $258K.
- What does operating lease liability payments - 2026 (lessee) mean?
- This represents the specific cash outflow commitment for operating leases scheduled for the calendar year 2026. It allows investors to isolate the impact of real estate and equipment lease obligations on the company's cash flow in a specific future period.